EU Approves Two-Dose COVID Vaccine Schedule for Young Children
The European Commission updated the Pfizer-BioNTech vaccine authorization for children aged 6 months through 4 years, reducing the primary series from three doses to two.
Updated on Nov. 2, 2026 in Children’s Health
Live Poll
Do you trust doctors' recommendations on childhood vaccines for your children?
On May 29, 2026, Pfizer and BioNTech announced that the European Commission approved an update to the Pfizer-BioNTech COVID-19 vaccine marketing authorization for children aged 6 months through 4 years. The primary series for this age group drops from three doses of 3 μg to two doses.
Why it matters
The change simplifies the vaccination schedule for young children and their families, and it eases management of vaccination programs for healthcare providers. The 10-μg dose for children aged 5 through 11 years remains unchanged.
The authorization, issued by the European Commission, cuts the primary series for children aged 6 months through 4 years from three 3-μg doses to two, while the single 10-μg dose for ages 5 through 11 stays the same. The source does not state the interval between doses or the specific trial outcomes behind the change.
The players
European Commission
The executive arm of the European Union, which granted the updated marketing authorization for the vaccine across EU Member States and several non-EU countries.
BioNTech
The German biotechnology company headquartered in Mainz that co-develops the Pfizer-BioNTech COVID-19 vaccine and serves as its Marketing Authorization Holder in several major markets.
Pfizer
The American pharmaceutical company based in New York that co-develops the Pfizer-BioNTech COVID-19 vaccine with BioNTech.
The details
The updated authorization is valid across all 27 EU Member States, Iceland, Liechtenstein and Norway, and is based on the Commission's review of available data, including safety data. BioNTech serves as Marketing Authorization Holder for the vaccine in the United States, the EU, the United Kingdom and other countries.
Timeline
May 29, 2026: Pfizer and BioNTech announced the European Commission approval of the pediatric vaccine update.
Big Picture
The change operates under the European Union's centralized marketing authorization procedure, which allows a single Commission decision to apply across all 27 Member States plus Iceland, Liechtenstein and Norway. It extends that pathway to revise the pediatric dosing schedule for children aged 6 months through 4 years.
Parents of children aged 6 months through 4 years in the covered regions now face a two-dose primary vaccination series rather than three. The single 10-μg dose for children aged 5 through 11 is unchanged, so families in that age group see no schedule change.
The takeaway
Parents of young children in covered European countries should check with their pediatrician about the updated two-dose schedule before scheduling the next vaccination. The change reflects a shift toward simpler pediatric dosing that can make it easier to keep vaccination appointments on time.
Further reading
Explore more on Children’s Health to see how vaccine schedules are set for young patients.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust doctors' recommendations on childhood vaccines for your children?
